STERIS plc Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
STERIS plc (STE) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $201.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-07
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $201.00M, a 12.92% increase year-over-year.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $220.30M, a 50.79% increase year-over-year.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $194.30M, a 12.12% increase year-over-year.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $192.50M, a 27.31% increase year-over-year.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2026 was $785.10M, a 27.43% increase from fiscal 2025.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $616.10M, a 62.09% increase from fiscal 2024.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $380.10M, a 259.22% increase from fiscal 2023.
- STERIS plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $105.81M, a 56.43% decline from fiscal 2022.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $201.00M 10-Q · filed 2026-08-07 | $421.30M derived: sum of 2 quarters · filed 2026-08-07 | $615.60M derived: sum of 3 quarters · filed 2026-08-07 | $808.10M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $220.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-29 | $414.60M derived: sum of 2 quarters · filed 2026-05-29 | $607.10M derived: sum of 3 quarters · filed 2026-05-29 | $785.10M 10-K · filed 2026-05-29 | ||||
| 2025-12-31 | $194.30M 10-Q · filed 2026-02-06 | $386.80M derived: sum of 2 quarters · filed 2026-02-06 | $564.80M 10-Q · filed 2026-02-06 | $710.90M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-09-30 | $192.50M 10-Q · filed 2025-11-06 | $370.40M 10-Q · filed 2025-11-06 | $516.60M derived: sum of 3 quarters · filed 2026-08-07 | $689.90M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $178.00M 10-Q · filed 2026-08-07 | $324.10M derived: sum of 2 quarters · filed 2026-08-07 | $497.40M derived: sum of 3 quarters · filed 2026-08-07 | $648.60M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $146.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-29 | $319.40M derived: sum of 2 quarters · filed 2026-05-29 | $470.60M derived: sum of 3 quarters · filed 2026-05-29 | $616.10M 10-K · filed 2026-05-29 | $616.07M 10-K · filed 2025-05-29 | |||
| 2024-12-31 | $173.30M 10-Q · filed 2026-02-06 | $173.28M 10-Q · filed 2025-02-07 | $324.50M derived: sum of 2 quarters · filed 2026-02-06 | $470.00M 10-Q · filed 2026-02-06 | $470.00M 10-Q · filed 2025-02-07 | $469.00M derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-09-30 | $151.20M 10-Q · filed 2025-11-06 | $151.17M 10-Q · filed 2024-11-07 | $296.70M 10-Q · filed 2025-11-06 | $296.71M 10-Q · filed 2024-11-07 | $295.70M derived: sum of 3 quarters · filed 2025-11-06 | $436.64M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $145.50M 10-Q · filed 2025-08-07 | $145.54M 10-Q · filed 2024-08-08 | $144.50M derived: sum of 2 quarters · filed 2025-08-07 | $285.44M derived: sum of 3 quarters · filed 2025-08-07 | $401.79M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$1.00M 10-K · filed 2024-05-29 | $139.94M derived: sum of 2 quarters · filed 2025-02-07 | $256.29M derived: sum of 3 quarters · filed 2025-02-07 | $380.10M 10-K · filed 2026-05-29 | $380.08M 10-K · filed 2024-05-29 | |||
| 2023-12-31 | $140.94M 10-Q · filed 2025-02-07 | $257.29M derived: sum of 2 quarters · filed 2025-02-07 | $381.08M 10-Q · filed 2025-02-07 | $568.04M derived: sum of 4 quarters · filed 2025-02-07 | ||||
| 2023-09-30 | $116.35M 10-Q · filed 2024-11-07 | $240.14M 10-Q · filed 2024-11-07 | $427.10M derived: sum of 3 quarters · filed 2024-11-07 | $550.42M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $123.79M 10-Q · filed 2024-08-08 | $310.75M derived: sum of 2 quarters · filed 2024-08-08 | $434.08M derived: sum of 3 quarters · filed 2024-08-08 | $118.85M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $186.96M 10-K · filed 2024-05-29 | $310.29M derived: sum of 2 quarters · filed 2024-05-29 | -$4.94M derived: sum of 3 quarters · filed 2024-05-29 | $105.81M 10-K · filed 2025-05-29 | ||||
| 2022-12-31 | $123.33M 10-K · filed 2024-05-29 | -$191.91M derived: sum of 2 quarters · filed 2024-05-29 | -$81.15M 10-Q · filed 2024-02-08 | -$29.10M derived: sum of 4 quarters · filed 2024-05-29 | ||||
| 2022-09-30 | -$315.23M 10-K · filed 2024-05-29 | -$204.48M 10-Q · filed 2023-11-07 | -$152.42M derived: sum of 3 quarters · filed 2024-05-29 | -$9.33M derived: sum of 4 quarters · filed 2024-05-29 | ||||
| 2022-06-30 | $110.75M 10-K · filed 2024-05-29 | $162.81M derived: sum of 2 quarters · filed 2024-05-29 | $305.90M derived: sum of 3 quarters · filed 2024-05-29 | $375.53M derived: sum of 4 quarters · filed 2024-05-29 | ||||
| 2022-03-31 | $52.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | $195.15M derived: sum of 2 quarters · filed 2024-05-29 | $264.77M derived: sum of 3 quarters · filed 2024-05-29 | $242.87M 10-K · filed 2024-05-29 | ||||
| 2021-12-31 | $143.09M 10-Q · filed 2023-02-08 | $212.72M derived: sum of 2 quarters · filed 2023-02-08 | $190.82M 10-Q · filed 2023-02-08 | $277.56M derived: sum of 4 quarters · filed 2023-05-26 | ||||
| 2021-09-30 | $69.63M 10-Q · filed 2022-11-09 | $47.72M 10-Q · filed 2022-11-09 | $134.47M derived: sum of 3 quarters · filed 2023-05-26 | $249.05M derived: sum of 4 quarters · filed 2023-05-26 | ||||
| 2021-06-30 | -$21.90M 10-Q · filed 2022-08-08 | $64.84M derived: sum of 2 quarters · filed 2023-05-26 | $179.43M derived: sum of 3 quarters · filed 2023-05-26 | $285.44M derived: sum of 4 quarters · filed 2023-05-26 | ||||
| 2021-03-31 | $86.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-26 | $201.33M derived: sum of 2 quarters · filed 2023-05-26 | $307.34M derived: sum of 3 quarters · filed 2023-05-26 | $396.87M 10-K · filed 2023-05-26 | ||||
| 2020-12-31 | $114.59M 10-Q · filed 2022-02-09 | $220.60M derived: sum of 2 quarters · filed 2022-02-09 | $310.13M 10-Q · filed 2022-02-09 | $308.72M 10-Q · filed 2021-02-09 | $433.40M derived: sum of 4 quarters · filed 2022-05-31 | |||
| 2020-09-30 | $106.01M 10-Q · filed 2021-11-08 | $195.54M 10-Q · filed 2021-11-08 | $194.13M 10-Q · filed 2020-11-06 | $318.81M derived: sum of 3 quarters · filed 2022-05-31 | $423.48M derived: sum of 4 quarters · filed 2022-05-31 | |||
| 2020-06-30 | $89.53M 10-Q · filed 2021-08-09 | $88.12M 10-Q · filed 2020-08-07 | $212.80M derived: sum of 2 quarters · filed 2022-05-31 | $317.47M derived: sum of 3 quarters · filed 2022-05-31 | $412.61M derived: sum of 4 quarters · filed 2022-05-31 | |||
| 2020-03-31 | $123.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-31 | $227.94M derived: sum of 2 quarters · filed 2022-05-31 | $323.08M derived: sum of 3 quarters · filed 2022-05-31 | $407.86M 10-K · filed 2022-05-31 | $407.81M 10-K · filed 2020-05-29 | |||
| 2019-12-31 | $104.67M 10-Q · filed 2021-02-09 | $199.81M derived: sum of 2 quarters · filed 2021-02-09 | $284.59M 10-Q · filed 2021-02-09 | $393.13M derived: sum of 4 quarters · filed 2021-05-28 | ||||
| 2019-09-30 | $95.14M 10-Q · filed 2020-11-06 | $179.92M 10-Q · filed 2020-11-06 | $288.47M derived: sum of 3 quarters · filed 2021-05-28 | $336.89M derived: sum of 4 quarters · filed 2021-05-28 | ||||
| 2019-06-30 | $84.78M 10-Q · filed 2020-08-07 | $193.32M derived: sum of 2 quarters · filed 2021-05-28 | $241.75M derived: sum of 3 quarters · filed 2021-05-28 | $319.25M derived: sum of 4 quarters · filed 2021-05-28 | ||||
| 2019-03-31 | $108.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-28 | $156.97M derived: sum of 2 quarters · filed 2021-05-28 | $234.47M derived: sum of 3 quarters · filed 2021-05-28 | $304.75M 10-K · filed 2021-05-28 | $305.08M 10-K · filed 2019-05-30 | |||
| 2018-12-31 | $48.43M 10-Q · filed 2020-02-10 | $125.92M derived: sum of 2 quarters · filed 2020-02-10 | $196.20M 10-Q · filed 2020-02-10 | |||||
| 2018-09-30 | $77.50M 10-Q · filed 2019-11-07 | $147.77M 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | $70.28M 10-Q · filed 2019-08-07 | |||||||
| 2018-03-31 | $291.62M 8-K · filed 2021-02-09 | |||||||
| 2017-03-31 | $110.63M 10-K · filed 2019-05-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |